摘要
Objective To evaluate the long-term efficacy of SCMC-ALL-2005 protocol in treatment of low-risk childhood acute lymphoblastic leukemia (ALL) .Methods From May 1,2005 to April 30,2009,387 patients enrolled into SCMC-ALL-2005 protocol.Based on the characteristics of cell morphology,immunology,cytogenetics and molecular biology and treatment response,158 patients were fit into the low-risk treatment group.All the cases were registered in pediatric oncology network
